Wernz J - Search Results

1

Phase II trial of paclitaxel and cisplatin in women with advanced breast cancer: an active regimen with limiting neurotoxicity.

Wasserheit C, Frazein A, Oratz R, Sorich J, Downey A, Hochster H, Chachoua A, Wernz J, Zeleniuch-Jacquotte A, Blum R, Speyer J. Wasserheit C, et al. Among authors: wernz j. J Clin Oncol. 1996 Jul;14(7):1993-9. doi: 10.1200/JCO.1996.14.7.1993. J Clin Oncol. 1996. PMID: 8683229 Clinical Trial.

2

Consolidation with intraperitoneal cisplatin in first-line therapy of advanced ovarian cancer.

Beller U, Speyer J, Colombo N, Sorich J, Wernz J, Hochster H, Zeleniuch-Jacquotte A, Porges R, Beckman EM. Beller U, et al. Among authors: wernz j. J Clin Oncol. 1991 May;9(5):809-17. doi: 10.1200/JCO.1991.9.5.809. J Clin Oncol. 1991. PMID: 2016624 Clinical Trial.

3

Phase I study of the combination of alpha-2 interferon and cisplatinum.

Walsh C, Speyer JL, Wernz J, Hochster H, Grossberg H, Chachoua A, Molinaro P, Meyers M, Blum RH. Walsh C, et al. Among authors: wernz j. J Biol Response Mod. 1989 Feb;8(1):11-5. J Biol Response Mod. 1989. PMID: 2921608

4

Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen.

Hochster H, Liebes L, Speyer J, Sorich J, Taubes B, Oratz R, Wernz J, Chachoua A, Raphael B, Vinci RZ, et al. Hochster H, et al. Among authors: wernz j. J Clin Oncol. 1994 Mar;12(3):553-9. doi: 10.1200/JCO.1994.12.3.553. J Clin Oncol. 1994. PMID: 8120553 Clinical Trial.

5

Effect of prolonged topotecan infusion on topoisomerase 1 levels: a phase I and pharmacodynamic study.

Hochster H, Liebes L, Speyer J, Sorich J, Taubes B, Oratz R, Wernz J, Chachoua A, Blum RH, Zeleniuch-Jacquotte A. Hochster H, et al. Among authors: wernz j. Clin Cancer Res. 1997 Aug;3(8):1245-52. Clin Cancer Res. 1997. PMID: 9815806 Clinical Trial.

6

ICRF-187 permits longer treatment with doxorubicin in women with breast cancer.

Speyer JL, Green MD, Zeleniuch-Jacquotte A, Wernz JC, Rey M, Sanger J, Kramer E, Ferrans V, Hochster H, Meyers M, et al. Speyer JL, et al. Among authors: wernz jc. J Clin Oncol. 1992 Jan;10(1):117-27. doi: 10.1200/JCO.1992.10.1.117. J Clin Oncol. 1992. PMID: 1727913 Clinical Trial.

7

Intraperitoneal carboplatin: favorable results in women with minimal residual ovarian cancer after cisplatin therapy.

Speyer JL, Beller U, Colombo N, Sorich J, Wernz JC, Hochster H, Green M, Porges R, Muggia FM, Canetta R, et al. Speyer JL, et al. Among authors: wernz jc. J Clin Oncol. 1990 Aug;8(8):1335-41. doi: 10.1200/JCO.1990.8.8.1335. J Clin Oncol. 1990. PMID: 2199620

8

Advanced ovarian cancer: three-year results of a 6-8 month, 2-drug cisplatin-containing regimen.

Piccart MJ, Speyer JL, Wernz JC, Noumoff J, Beller U, Beckman M, Dubin N, Demopoulos R, Muggia F. Piccart MJ, et al. Among authors: wernz jc. Eur J Cancer Clin Oncol. 1987 Jun;23(6):631-41. doi: 10.1016/0277-5379(87)90258-6. Eur J Cancer Clin Oncol. 1987. PMID: 3653186

9

Good tolerance of weekly oral idarubicin: (4-demethoxydaunorubicin): a phase I study with pharmacology.

Hochster H, Green M, Liebes L, Speyer JL, Wernz J, Blum R, Muggia F. Hochster H, et al. Among authors: wernz j. Cancer Chemother Pharmacol. 1990;26(4):297-300. doi: 10.1007/BF02897234. Cancer Chemother Pharmacol. 1990. PMID: 2369795

10

Phase II trial of ICRF-187 in patients with acquired immune deficiency related Kaposi's sarcoma (AIDS-KS).

Chachoua A, Green M, Wernz J, Muggia F. Chachoua A, et al. Among authors: wernz j. Invest New Drugs. 1989 Nov;7(4):327-31. doi: 10.1007/BF00173762. Invest New Drugs. 1989. PMID: 2513285

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

49 results

Search Page

Filters